Which population is highlighted for the screening of phenylketonuria?

The screening for phenylketonuria (PKU) is specifically emphasized for newborns because early detection is crucial for the prevention of severe neurological damage that can result from the condition. PKU is a genetic disorder that affects the metabolism of the amino acid phenylalanine, leading to its accumulation when not properly managed. By screening newborns shortly after birth, healthcare providers can identify those who are affected and initiate dietary interventions quickly. This early management significantly reduces the risk of serious health issues associated with untreated PKU.

In contrast, adults, children, and adolescents are typically not the focus of routine screening for PKU since the condition is usually detectable at birth and its effects manifest early in life. The primary goal of screening is to catch the disorder as early as possible in newborns, allowing for interventions before any irreversible damage occurs.